← All trials
NCT05979038
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 10, 2023
- Primary completion
- Jun 15, 2024
- Completion date
- Jul 10, 2024
- First posted
- Aug 7, 2023
- Last posted
- Sep 13, 2023
- Enrollment
- 110
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- German University in CairoLead sponsor
- German University in CairoReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.